BioStem Technologies, Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, BioStem Technologies is in Stage 4, the downtrend phase, now in week 2 (since Oct 9, 2026). It closed at $1.66, 79.8% below its 52-week high and below its 200-day average, which is falling.

$1.66

-1.19% today

$31.0M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is BSEM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 30w

S2 26w

S4 27w

S4 23w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 5w → S1 5w → S2 30w → S3 9w → S2 26w → S3 5w → S2 1w → S3 5w → S4 6w → S1 8w → S4 27w → S1 10w → S4 23w → S1 3w → S4 2w current

Total tracked: 166 weeks across 15 stage runs.

BSEM among Biotechnology416th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…416	BSEMBioStem Technologies, Inc.	Stage 4 · wk 2	16	−56.3%

vs 52W High

-79.8%

$1.54 lo$8.20 hi

79.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-61.4%

200 DMA: $4.30 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.32x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-56.3%

-58.6%

-62.7%

YTD

-57.5%

-68.7%

Scan Membership

Breakout Watch

Latest: 2025-02-25

7 appearances in last 60 days. First seen: 2019-12-17.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.32x

2026-10-21S4

Wk 2 · Vol 1.29x

2026-10-20S4

Wk 2 · Vol 1.09x

2026-10-19S4

Wk 2 · Vol 2.74x

2026-10-16S4

Wk 2 · Vol 0.22x

2026-10-15S4

Wk 1 · Vol 0.69x

2026-10-14S4

Wk 1 · Vol 0.47x

2026-10-13S4

Wk 1 · Vol 0.76x

2026-10-12S4

Wk 1 · Vol 0.25x

2026-10-09S41→4

Wk 1 · Vol 0.44x

2026-10-08S1

Wk 4 · Vol 1.76x

2026-10-07S1

Wk 4 · Vol 0.61x

Moving averages & range

50 DMA

$3.30

200 DMA

$4.30

52W High

$8.20

52W Low

$1.54

5D Low

$1.54

Resistance levels (recent highs)

20d High

$4.14

60d High

$4.74

120d High

$5.08

250d High

$8.20

Next resistance

+149.4%

to 20d High

P/E (TTM)

1.9

Forward 5.7

ROE

-74.7%

Profit margin -81.8%

Dividend Yield

0.00%

P/B 1.1

BioStem Technologies: quick answers

What stage is BioStem Technologies in?

As of Oct 22, 2026, BioStem Technologies (BSEM) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 9, 2026 and is in week 2. What the four stages mean

Is BioStem Technologies in an uptrend?

No. BioStem Technologies is in a Stage 4 downtrend. It trades 61.4% below its 200-day average, which is falling.

How far is BioStem Technologies from its 52-week high?

BioStem Technologies closed at $1.66 on Oct 22, 2026, 79.8% below its 52-week high of $8.20. Its 52-week low is $1.54.

How has BioStem Technologies performed over the past year?

As of Oct 22, 2026, BioStem Technologies is down 68.7% over the past year and down 57.5% so far in 2026.

Which sector and industry is BioStem Technologies in?

BioStem Technologies is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.